HeartSciences (NASDAQ:HSCS – Get Free Report) and Tempus AI (NASDAQ:TEM – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.
Volatility and Risk
HeartSciences has a beta of 2.56, meaning that its stock price is 156% more volatile than the S&P 500. Comparatively, Tempus AI has a beta of 4.86, meaning that its stock price is 386% more volatile than the S&P 500.
Insider and Institutional Ownership
17.2% of HeartSciences shares are owned by institutional investors. Comparatively, 24.2% of Tempus AI shares are owned by institutional investors. 1.8% of HeartSciences shares are owned by insiders. Comparatively, 26.3% of Tempus AI shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| HeartSciences | N/A | N/A | -$8.77 million | ($8.30) | -0.30 |
| Tempus AI | $693.40 million | 19.52 | -$705.81 million | ($1.19) | -63.92 |
HeartSciences has higher earnings, but lower revenue than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings for HeartSciences and Tempus AI, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| HeartSciences | 1 | 0 | 2 | 0 | 2.33 |
| Tempus AI | 1 | 7 | 7 | 0 | 2.40 |
HeartSciences currently has a consensus target price of $10.50, indicating a potential upside of 315.02%. Tempus AI has a consensus target price of $80.00, indicating a potential upside of 5.18%. Given HeartSciences’ higher probable upside, equities analysts plainly believe HeartSciences is more favorable than Tempus AI.
Profitability
This table compares HeartSciences and Tempus AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| HeartSciences | N/A | -383.38% | -145.28% |
| Tempus AI | -18.45% | -73.21% | -13.78% |
Summary
Tempus AI beats HeartSciences on 9 of the 13 factors compared between the two stocks.
About HeartSciences
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
About Tempus AI
Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.
Receive News & Ratings for HeartSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartSciences and related companies with MarketBeat.com's FREE daily email newsletter.
